Literature DB >> 22922660

Bipolar affective disorder and early dementia onset in a male patient with SHANK3 deletion.

Ksenija Vucurovic1, Emilie Landais, Cécile Delahaigue, Julien Eutrope, Anouck Schneider, Camille Leroy, Hamza Kabbaj, Jacques Motte, Dominique Gaillard, Anne-Catherine Rolland, Martine Doco-Fenzy.   

Abstract

The SHANK3 protein is a scaffold protein known to stabilize metabotropic glutamate receptor mGluR5 in the post-synaptic membrane of neurons. It is associated with genetic vulnerability in autism and schizophrenia. Here we report the case of an 18 year-old male patient who displayed psychiatric features of bipolar affective disorder associated with early setting of dementia. This mental status is related to sporadic occurrence of SHANK3 gene complex multiple deletions. A low beta amyloid protein rate (479 mg/L) found in cerebrospinal fluid suggests a possible link between SHANK3 deletion syndrome-associated regression and dementia of Alzheimers's type. In addition, we propose an overview of the phenotype related to SHANK3 deletion.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22922660     DOI: 10.1016/j.ejmg.2012.07.009

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  23 in total

Review 1.  Animal models of bipolar mania: The past, present and future.

Authors:  R W Logan; C A McClung
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 2.  Phelan-McDermid Syndrome and SHANK3: Implications for Treatment.

Authors:  Jesse L Costales; Alexander Kolevzon
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

Review 3.  Phelan McDermid Syndrome: From Genetic Discoveries to Animal Models and Treatment.

Authors:  Hala Harony-Nicolas; Silvia De Rubeis; Alexander Kolevzon; Joseph D Buxbaum
Journal:  J Child Neurol       Date:  2015-09-08       Impact factor: 1.987

4.  Deficiency of Shank2 causes mania-like behavior that responds to mood stabilizers.

Authors:  Andrea L Pappas; Alexandra L Bey; Xiaoming Wang; Mark Rossi; Yong Ho Kim; Haidun Yan; Fiona Porkka; Lara J Duffney; Samantha M Phillips; Xinyu Cao; Jin-Dong Ding; Ramona M Rodriguiz; Henry H Yin; Richard J Weinberg; Ru-Rong Ji; William C Wetsel; Yong-Hui Jiang
Journal:  JCI Insight       Date:  2017-10-19

5.  Novel Shank3 mutant exhibits behaviors with face validity for autism and altered striatal and hippocampal function.

Authors:  Thomas C Jaramillo; Haley E Speed; Zhong Xuan; Jeremy M Reimers; Christine Ochoa Escamilla; Travis P Weaver; Shunan Liu; Irina Filonova; Craig M Powell
Journal:  Autism Res       Date:  2016-08-05       Impact factor: 5.216

Review 6.  Framework for assessing individuals with rare genetic disorders associated with profound intellectual and multiple disabilities (PIMD): the example of Phelan McDermid Syndrome.

Authors:  Latha Soorya; Jill Leon; M Pilar Trelles; Audrey Thurm
Journal:  Clin Neuropsychol       Date:  2017-12-21       Impact factor: 3.535

Review 7.  Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies.

Authors:  Irina Esterlis; Sophie E Holmes; Priya Sharma; John H Krystal; Christine DeLorenzo
Journal:  Biol Psychiatry       Date:  2017-09-19       Impact factor: 13.382

8.  Eighteen-year-old man with autism, obsessive compulsive disorder and a SHANK2 variant presents with severe anorexia that responds to high-dose fluoxetine.

Authors:  Zhen A Lu; Weiyi Mu; Lauren M Osborne; Zachary A Cordner
Journal:  BMJ Case Rep       Date:  2018-07-09

Review 9.  Association of SHANK Family with Neuropsychiatric Disorders: An Update on Genetic and Animal Model Discoveries.

Authors:  Lily Wan; Du Liu; Wen-Biao Xiao; Bo-Xin Zhang; Xiao-Xin Yan; Zhao-Hui Luo; Bo Xiao
Journal:  Cell Mol Neurobiol       Date:  2021-02-17       Impact factor: 5.046

10.  Post-transcriptional regulation of SHANK3 expression by microRNAs related to multiple neuropsychiatric disorders.

Authors:  Su-Yeon Choi; Kaifang Pang; Joo Yeon Kim; Jae Ryun Ryu; Hyojin Kang; Zhandong Liu; Won-Ki Kim; Woong Sun; Hyun Kim; Kihoon Han
Journal:  Mol Brain       Date:  2015-11-16       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.